USCOM LIMITED — Regulatory Filings 2012

May 16, 2012

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

New Research - USCOM Can Replace Invasive Cardiac Monitors

Thursday 17th of May 2012:

Noninvasive Cardiac Output Monitoring manufacturer Uscom Ltd (ASX code: UCM) today announced the publication of new peer reviewed research confirming its cardiac monitor, the USCOM 1A, was more accurate than current technologies used to monitor cardiac output.

The results of the study by the prestigious Howard Florey Institute in Melbourne and The University of Queensland in Brisbane is published in the latest Journal of Critical Care Research and Practice.

The current gold standard cardiac monitor is the Pulmonary Artery Catheter (PAC) which involves insertion of a catheter into a patient’s neck or groin and then positioning the catheter in their arteries through the heart, while USCOM simply involves placing a small ultrasound probe on the chest. This study compared the two methods. The researchers surgically implanted accurate measurement devices onto the great cardiac arteries of sheep, and then monitored their cardiac output using USCOM and PAC at rest and as medications were introduced. They found that USCOM had a 1% error compared with the surgical device, while the PAC error was 17%, and that USCOM was 6 to 8 times more accurate than the PAC for detecting changes associated with the common drugs used in cardiovascular management. The study concluded that USCOM was a noninvasive and accurate replacement for PAC.

Professor Malcolm West, the Mayne Professor of Medicine and Head of the Discipline of Medicine at the University of Queensland and an author of the paper said “The USCOM device is a simple method of accurately and noninvasively measuring central circulation, a goal of cardiology for many years. To be noninvasive is a great advantage over the PAC, to be noninvasive and much more accurate means the device has the potential to change the way we approach management of many cardiovascular diseases including sepsis, heart failure and hypertension.”

The paper found that USCOM’s accuracy is unequalled by other clinical methods which explains results found at the Cedars Sinai Intensive Care Department in Los Angeles, published in 2008 in the American Journal of Surgery which found that “USCOM could reliably replace PAC in most clinical situations”. The Swan Ganz PAC has been the standard of human cardiac output measurement since its introduction by Drs Swan and Ganz in the Cedars Sinai Intensive Care Department in 1970. The PAC is associated with a significant risk of death and infection and is confined to critical care use in adults, while alternatively USCOM is totally noninvasive and can be used in a variety of clinical and research applications in adults, children and neonates.

Uscom Chief Executive Rob Phillips said, “This new study adds to the growing global body of independent evidence which demonstrates that our USCOM device offers critical care clinicians a new gold standard for cardiovascular monitoring which can replace costly and dangerous catheter based technologies”.

“It confirms that our growing worldwide customer base has the very best tool available to guide lifesaving cardiovascular treatments and improve the management of critical and widespread diseases such as sepsis, heart failure and hypertension”.

Mr Phillips also said the data confirmed Uscom’s marketing strategy to focus on the needs of hospitals worldwide for more accurate, noninvasive techniques that improve patient care at the same time as reducing the risk of infections and mortality and reducing costs.

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

Uscom's non-invasive system is an Australian developed, patent protected technology that uses external ultrasound similar to that used in pregnancy. The ultrasound signal bounces off the red blood cells as they flow across the cardiac valves producing a unique echo from which the device can then count the cells with high accuracy. The USCOM monitor has many applications ranging from paediatrics, critical care, anaesthesia and emergency medicine. New markets are centred on sepsis, heart failure and hypertension, the great global challenges of health care.

References:

Jain S, Vafa A, Margulies DR, Liu W, Wilson MT, Allins AD. Noninvasive Doppler ultrasonography for assessing cardiac function: can it replace the Swan-Ganz catheter? Am J Surgery 2008:196(Dec);961-968.

Thiel SW, Kollef MH, Isakow W. Non-invasive stroke volume measurement and passive leg raising predict volume responsiveness in medical ICU patients: an observational cohort study. Critical Care 2009;39:666-688.

Phillips RA, Hood SG, Jacobson BM, West MJ, Wan L, May CN. Pulmonary artery catheter (PAC) accuracy and efficacy compared with flow probe and transcutaneous Doppler (USCOM): An ovine validation. Crit Care Res Prac 2012;doi:10.1155/2012/621496.

About Uscom

Uscom Limited is an Australian medical device company which listed on the Australian Stock Exchange in December 2003. Uscom has developed a Noninvasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

USCOM has global regulatory approval and the device is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Tom Rowe Company Secretary secretary@uscom.com.au